A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Boehringer Ingelheim
- Study ID
- NCT07497087
- Phase
- PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Placebo matching nerandomilast formulation 1 — DRUGFilm-coated tablets
- Placebo matching nerandomilast formulation 2 — DRUGFilm-coated tablets
- Nerandomilast formulation 1 — DRUGFilm-coated tablets
- Nerandomilast formulation 2 — DRUGFilm-coated tablets
Study Details
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day. Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Key Dates
- Start date
- Jun 22, 2026
- Status verified
- Jun 2026
- Primary completion
- Feb 26, 2030
- Completion
- Mar 17, 2030
Study Design
- Enrollment
- 448 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Placebo
- Experimental: Nerandomilast
Primary Outcome Measure
Time to the first occurrence of disease progression or all-cause death [ Time Frame: up to 4 years ]
Central Contacts
- Boehringer Ingelheim1-800-243-0127
Locations (30)
Find similar trials in Birmingham, AL
Related Studies
- New Orleans Pulmonary Hypertension BiobankRecruiting · Louisiana State University Health Sciences Center in New Orleans · New Orleans, Louisiana
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisPHASE2 · Recruiting · Paul Szabolcs · Pittsburgh, Pennsylvania
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisPHASE2 · Recruiting · Hospital for Special Surgery, New York · New York, New York
- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesPHASE2 · Recruiting · Stephan Grupp MD PhD · Philadelphia, Pennsylvania